


WHAT IS CLAIMED IS:

- 1 1. A free base crystalline form of Compound 1



(Compound 1),

- 3 which is substantially free of other forms of Compound 1.

- 1 2. The free base crystalline form of claim 1, characterized by an X-ray
2 powder diffraction (XRPD) pattern comprising peaks at 8.1, 8.4, 14.1, 16.9, and 19.0 **degrees 2 θ**
3 (**$\pm$ 0.2 degrees 2 θ**).

3. The free base crystalline form of claim 2, further characterized by XRPD peaks at 12.4, 15.2, 16.1, 24.4, and 24.7 degrees 2 θ ($\pm$ 0.2 degrees 2 θ)

4. The free base crystalline form of claim 1, characterized by an X-ray powder diffraction pattern substantially in accordance with **FIG. 1**.

- 1 5. The free base crystalline form of any one of claims 1 to 4, further
2 characterized by a differential scanning calorimetry thermogram (DSC) comprising an
3 endothermic peak at around 216 °C.

- 1 **6.** The free base crystalline form of any one of claims **1** to **4**, further
2 characterized by a melting point onset of about 213 °C as determined by differential scanning
3 calorimetry thermogram (DSC).

- 1 7. The free base crystalline form of any one of claims **1** to **4**, further
2 characterized by a DSC substantially in accordance with **FIG. 2**.

1 **8.** A pharmaceutical composition comprising the free base crystalline form
2 of Compound 1 according to any one of claims **1** to **7** and at least one pharmaceutically
3 acceptable excipient.

1 **9.** An aqueous suspension comprising the free base crystalline form of
2 Compound 1 according to any one of claims **1** to **7** and at least one excipient.

1 **10.** The aqueous suspension of claim **9**, wherein the at least one excipient is at
2 least one suspending agent and/or at least one wetting agent.

1 **11.** A method for treating an individual suffering from or susceptible to a
2 disease or disorder involving pathologic activation of C5a receptors, comprising administering to
3 the individual an effective amount of a free base crystalline form of Compound 1 according to
4 any one of claims **1** to **7**.

1 **12.** The method of claim **11**, wherein the disease or disorder is an
2 inflammatory disease or disorder.

1 **13.** The method of claim **12**, wherein the disease or disorder is selected from
2 the group consisting of neutropenia, sepsis, septic shock, Alzheimer's disease, multiple sclerosis,
3 stroke, inflammatory bowel disease, age-related macular degeneration, chronic obstructive
4 pulmonary disorder, inflammation associated with burns, lung injury, osteoarthritis, atopic
5 dermatitis, chronic urticaria, ischemia-reperfusion injury, acute respiratory distress syndrome,
6 systemic inflammatory response syndrome, multiple organ dysfunction syndrome, tissue graft
7 rejection, cancer and hyperacute rejection of transplanted organs.

1 **14.** The method of claim **11**, wherein the disease or disorder is a
2 cardiovascular or cerebrovascular disorder.

1 **15.** The method of claim **14**, wherein the disease or disorder is selected from
2 the group consisting of myocardial infarction, coronary thrombosis, vascular occlusion, post-
3 surgical vascular reocclusion, atherosclerosis, traumatic central nervous system injury and
4 ischemic heart disease.

1 **16.** The method of claim **11**, wherein the disease or disorder is an autoimmune
2 disorder.

1 **17.** The method of claim **16**, wherein the disease or disorder is selected from
2 the group consisting of rheumatoid arthritis, C3 glomerulopathy (C3G), hidradenitis suppurativa
3 (HS), systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis,
4 lupus glomerulonephritis, psoriasis, immunoglobulin A (IgA) nephropathy, Crohn's disease,
5 vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma,
6 pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and
7 thrombocytopenic states, Goodpasture's syndrome, immunovascularitis, tissue graft rejection and
8 hyperacute rejection of transplanted organs.

1 **18.** The method of claim **11**, wherein the disease or disorder is a pathologic
2 sequelae associated with the group consisting of insulin-dependent diabetes, mellitus, lupus
3 nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, contact sensitivity
4 responses, and inflammation resulting from contact of blood with artificial surfaces.

1 **19.** The method of claim **11**, wherein the disease or disorder is selected from
2 the group consisting of anti-neutrophil cytoplasmic antibody associate (ANCA) vasculitis, C3
3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.

1 **20.** The method of claim **11**, wherein the disease or disorder is anti-neutrophil
2 cytoplasmic antibody associate (ANCA) vasculitis.

1 **21.** The method of claim **11**, wherein the disease or disorder is granulomatosis
2 with polyangiitis.

1 **22.** The method of claim **11**, wherein the disease or disorder is microscopic
2 polyangiitis.

1 **23.** The method of claim **11**, wherein the disease or disorder is C3
2 glomerulopathy.

1 **24.** The method of claim **11**, wherein the disease or disorder is hidradenitis
2 suppurativa.

1 **25.** The method of claim **11**, wherein the disease or disorder is lupus nephritis.

1 **26.** The method of any one of claims **11** to **25**, further comprising
2 administering to the individual an effective amount of one or more additional therapeutic agents.

1 **27.** The method of claim **26**, wherein the one or more additional therapeutic
2 agent is rituximab.

1 **28.** The method of claim **26**, wherein the one or more additional therapeutic
2 agent is cyclophosphamide.